Skip to main content
Sign In
 

Clinical Research: Safety Study Monitoring Bayhill-3021 in Type 1 Diabetes Mellitus

The BHT Research Study


 

Principal Investigator: Peter Gottlieb, COMIRB #: 06-0627

  • The BHT Research Study is looking for people diagnosed with type 1 diabetes who may still producing some of their own insulin.
  • This research study will test the medication BHT-3021 to see if it is safe.
  • Secondarily, the research study will see if BHT-3021 can help maintain the body’s ability to produce some insulin.

Why should you consider this study?

  • You will be part of a research study to see if we can stop your slow down your  body’s attack of on the cells that produce insulin.
  • If the study drug is successful, you may have an easier time managing your diabetes.
  • The information from this study may help other people with diabetes.

Who can sign up for this study?

  • People who have been diagnosed with Type 1 Diabetes.
  • 18 - 45 years old.
  • 40 years old or less at the time of diagnosis with type 1 diabetes.
  • People who may be producing some of their own insulin.

What will happen in this study?

  • You will be assessed for general health and diabetes care.
  • If you qualify, you will receive 12 weekly treatments with study medication or fake medication.
  • If you receive the fake medication, you can receive the study medication after one year.
  • You will be monitored for 2-5 years to look at your overall diabetes health.

Who should I call with questions or to schedule an appointment?

Sandy Barry: 303-724-7501 or Sandra.Barry@ucdenver.edu
Lisa Meyers: 303.724.6893 or Lisa.Meyers@ucdenver.edu